Eli Lilly collaborates with Walmart to offer Zepbound, an obesity medication, for direct-to-consumer pick-up pricing at Walmart pharmacies, expanding nationwide access and lowering patient costs.
October 31, 2025
Source:
Eli Lilly and Co.
New Pharmacy Pickup Option for Obesity Medication
Eli Lilly and Walmart have launched a new program allowing patients to collect Zepbound (tirzepatide) at Walmart pharmacies nationwide, starting mid-November 2025. This initiative is the first time consumers can access LillyDirect’s direct-to-consumer pricing for Zepbound vials through a physical retail outlet (PRNewswire).
Direct-to-Consumer Pricing Model
Price starts at $349/month for the lowest dose of Zepbound.
Patients need a valid prescription to qualify for self-pay pricing.
This price reflects a 50% or greater discount versus list prices of other GLP-1 drugs used for obesity (Fierce Healthcare).
The self-pay method means no need for insurance coverage, granting access to individuals whose insurance may not cover weight loss treatments.
Keep up with the story. Subscribe to the PR+ free daily newsletter
Source:
Walmart Inc.
Strategic Collaboration Details
Walmart brings its 4,600 pharmacy locations into the program, increasing geographic reach and making Zepbound accessible to millions more Americans battling obesity (iHeart).
Obesity and Diabetes Drug Market Impact
LillyDirect’s rapid growth: Already responsible for 35% of new Zepbound scripts in Q2 2025.
Competitive landscape: This partnership strengthens Eli Lilly’s position against Novo Nordisk and other major competitors.
How to Access
Obtain a valid Zepbound prescription.
Order via the LillyDirect platform.
Pick up the medication at the nearest Walmart pharmacy—no insurance required.
Read More
Source:
Eli Lilly and Co.
Share this news:
